• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles

    6/4/25 7:00:00 AM ET
    $BHST
    Get the next $BHST alert in real time by email

    Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.

    Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.

    Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.*

    "Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use," said Ilan Sobel, CEO of BioHarvest. "The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend.

    "This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions," concluded Sobel.

    *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    About Informed Sport

    Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. https://sport.wetestyoutrust.com/

    About BioHarvest Sciences Inc.

    BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

    Forward-Looking Statements

    Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

    BioHarvest Corporate Contact:
    Dave Ryan, VP Investor Relations
    +1 (604) 622-1186
    [email protected]

    Investor Relations Contact:
    Lucas A. Zimmerman
    Managing Director
    MZ Group - MZ North America
    +1 (949) 259-4987
    [email protected]

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254440

    Get the next $BHST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    2/19/2026$10.00Buy
    Roth Capital
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026Time: 4:30 PM Eastern TimeWebcast link: https://events.q4inc.com/attendee/512060117The Earnin

    3/17/26 8:30:00 AM ET
    $BHST

    BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.Mr. Tsur has served on BioHarvest's Board since 2021 and has contributed meaningfully to the Company's strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.Zaki Rakib, Chair

    3/5/26 7:30:00 AM ET
    $BHST

    BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event. 38th Annual Roth Conference for Growth CompaniesDate: March 22-24, 2026Location: The Ritz-Carlton Laguna Niguel- Dana Point, CAFormat: 1x1 MeetingsSobel said: "I am pleased to announce our invitation to the 38th Annual Ro

    3/3/26 8:30:00 AM ET
    $BHST

    $BHST
    SEC Filings

    View All

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    3/17/26 3:40:06 PM ET
    $BHST

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    3/16/26 2:11:11 PM ET
    $BHST

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    3/6/26 4:24:27 PM ET
    $BHST

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on BioHarvest Sciences with a new price target

    Roth Capital initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $10.00

    2/19/26 7:50:59 AM ET
    $BHST

    Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

    Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

    5/5/25 8:30:45 AM ET
    $BHST

    Maxim Group initiated coverage on BioHarvest Sciences with a new price target

    Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

    12/18/24 8:10:03 AM ET
    $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    View All

    BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.Mr. Tsur has served on BioHarvest's Board since 2021 and has contributed meaningfully to the Company's strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.Zaki Rakib, Chair

    3/5/26 7:30:00 AM ET
    $BHST

    BioHarvest Announces Appointment of Sharon Malka to Board of Directors

    Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

    1/22/25 8:30:00 AM ET
    $BHST

    $BHST
    Financials

    Live finance-specific insights

    View All

    BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026Time: 4:30 PM Eastern TimeWebcast link: https://events.q4inc.com/attendee/512060117The Earnin

    3/17/26 8:30:00 AM ET
    $BHST

    BioHarvest Sciences Reports Third Quarter 2025 Financial Results

    Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year GrowthCompany Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in SeptemberVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025.Third Quarter 2025 Operational HighlightsAll figu

    11/13/25 4:05:00 PM ET
    $BHST

    BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, November 13, 2025 to discuss the Company's third quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate,

    11/4/25 7:30:00 AM ET
    $BHST